
Bulletin from the Annual General Meeting of BiBBInstruments AB

The shareholders of BiBBInstruments AB ("BiBB" or the "Company") held the Annual General Meeting on 12 June 2026 in Lund, at which the following principal resolutions were passed. The complete proposed resolutions are set out in the notice convening the meeting, which was published on 11 May.

Adoption of the income statement and balance sheet and discharge from liability

The Meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet in accordance with the annual report presented. The members of the Board of Directors and the Managing Director were granted discharge from liability for the financial year 2025.

Appropriation of the Company's result

The Meeting resolved, in accordance with the proposal of the Board of Directors, that no dividend be paid for the financial year 2025 and that the Company's result be appropriated in accordance with the Board of Directors' proposal in the annual report.

Number of Board members and auditors

The Meeting resolved that the Board of Directors shall consist of four (4) members and that one (1) auditor be appointed.

Election of the Board of Directors and auditor and fees

The Meeting resolved to re-elect Erik von Schenck, Sara Lindroth, Kristian Waldeck and Charles Walther as ordinary members of the Board of Directors. Erik von Schenck was re-elected as Chairman of the Board.

Fees to the Board of Directors for the period until the end of the next Annual General Meeting were resolved to be paid in the amount of SEK 250,000 to the Chairman of the Board and SEK 150,000 to each of the Board members Sara Lindroth, Charles Walther and Kristian Waldeck.

The Meeting further resolved to re-elect Baker Tilly Saxos KB, with Niclas Frank as auditor in charge, as the Company's auditor until the end of the Annual General Meeting held in the next financial year. The auditor shall be remunerated in accordance with approved invoice and customary charging principles.

Introduction of instructions for the nomination committee

The Meeting resolved, in accordance with the proposal of the Board of Directors, to introduce a nomination committee and instructions for the nomination committee. The nomination committee shall consist of three members appointed by the three largest shareholders by voting power as at the end of the third quarter of each year, in accordance with the principles set out in the nomination committee instructions.

Amendment of the articles of association

The Meeting resolved, in accordance with the proposal of the Board of Directors, to amend § 4 of the articles of association so that the share capital shall be not less than SEK 1,609,831.49 and not more than SEK 6,439,325.96 and the number of shares not less than 160,983,149 and not more than 643,932,596.

Reduction of the share capital

The Meeting resolved, in accordance with the proposal of the Board of Directors, to reduce the Company's share capital by SEK 12,073,736.175, from SEK 13,683,567.665 to SEK 1,609,831.49, for allocation to unrestricted equity. The reduction is carried out without cancellation of shares, whereby the quotient value changes from approximately SEK 0.085 to SEK 0.01 per share. The resolution is conditional upon authorisation from the Swedish Companies Registration Office (Bolagsverket).

The resolutions on the amendment of the articles of association and the reduction of the share capital were supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the Meeting.

For more information, please contact:

Fredrik Lindblad, CEO
Email: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

This is a translation of the Swedish press release. In the event of any discrepancy, the Swedish language version shall prevail.

The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor upon publication of this press release.

About BiBBInstruments AB

BiBBInstruments AB is a cancer diagnostics company developing and manufacturing EndoDrill®, the world's first series of market-cleared powered endoscopic biopsy instruments. EndoDrill® is designed to obtain core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancers in organs such as the stomach, pancreas, liver, lungs, and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments within modern endoscopy. BiBB received FDA 510(k) clearance for its first instrument, EndoDrill® GI, in 2023 and CE marking under the European Medical Device Regulation (MDR) in 2024 for all three product variants – EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO. As such, EndoDrill® is the first powered biopsy system cleared in both the United States and Europe. The U.S. launch of EndoDrill® GI commenced during the second half of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant pathologist at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund, Sweden, and its shares are listed on Spotlight Stock Market (ticker: BIBB).